Trials / Unknown
UnknownNCT02599064
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- RXi Pharmaceuticals, Corp. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular age-related macular degeneration (NVAMD).
Detailed description
Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of RXI-109 when administered by intravitreal injection. Evaluate the clinical activity of single and multiple doses of RXI-109 when administered by intravitreal injection. Study participation is intended to be seven months from time of initial treatment with RXI-109.
Conditions
- Age-related Macular Degeneration
- Subfoveal Choroidal Neovascularization
- Subretinal Scarring
- Subretinal Fibrosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RXI-109 | RXI-109 dosed intravitreally to subjects with NVAMD |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-04-01
- Completion
- 2018-05-01
- First posted
- 2015-11-06
- Last updated
- 2018-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02599064. Inclusion in this directory is not an endorsement.